Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial
Sodium glucose co-transporter 2 inhibitors promote osmotic/natriuretic diuresis and reduce excess fluid volume, and this improves cardiovascular outcomes, including hospitalization for heart failure. We sought...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Atsushi Tanaka, Michio Shimabukuro, Hiroki Teragawa, Yosuke Okada, Toshinari Takamura, Isao Taguchi, Shigeru Toyoda, Hirofumi Tomiyama, Shinichiro Ueda, Yukihito Higashi and Koichi Node Tags: Original investigation Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Heart | Heart Failure | Jardiance | Sodium